The independent source for health policy research, polling, and news.
401 - 420 of 1,292 Results
Spun off from the ailing but not-quite-dead Build Back Better legislation, a popular proposal to cap out-of-pocket insulin costs at $35 a month faces tough political realities that could kill it.
Gov. Gavin Newsom has launched several initiatives to cut rising drug prices, but the savings haven’t been as monumental as he promised. And his plan to have California make its own generic drugs hasn’t gotten off the ground.
The Department of Labor issued rules in July clarifying that health plans need to cover the costs of prescription drugs proven to prevent HIV infection, along with related lab tests and medical appointments, at no cost to patients. More than half a year later, the erroneous billing continues.
What a difference a year makes. The speech was delivered to a largely unmasked crowd of lawmakers, justices, and Cabinet members in the House chamber.
After a troubled start to the new Medi-Cal prescription drug program, the state’s contractor has hired staffers to reduce wait times for medication approvals and patients seeking help. But some doctors and clinics report that patients continue to face delays.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
As the pandemic wanes, for now, the ever-rising cost of health care is again taking center stage. Meanwhile, a year into the Biden administration, the FDA finally has a Senate-confirmed commissioner, Dr. Robert Califf. Tami Luhby of CNN, Sarah Karlin-Smith of the Pink Sheet, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Hannah Wesolowski of the National Alliance on Mental Illness, about how the pandemic has worsened the nation’s mental health crisis and what can be done about it.
An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimer’s drug that scientists say has not been proven to work.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Problems with California’s new Medicaid prescription drug program are preventing thousands of patients from getting their medications, including some life-saving ones. State officials say they’re working on fixes.
The Centers for Disease Control and Prevention quietly changed its guidance to allow an extra shot in certain cases, but some pharmacy personnel are confused about who is eligible.
A KHN reporter had written for years about the people left behind by the absurdly complex and expensive U.S. health care system. Then he found himself navigating that maze as he tried to get his insulin prescription filled.
The top 12 states using antibody therapies produced by Regeneron and Lilly — which research shows don’t work against the omicron variant — include several Southern states with some of the nation’s lowest vaccination rates, but also California, which ranks among the top 20 for fully vaccinated residents.
Just 18% of 5- to 11-year-olds are fully vaccinated, with rates varying significantly across the country, a KHN analysis of federal data shows. Pediatricians say the slow pace and geographic disparities are alarming, especially against the backdrop of record numbers of cases and pediatric hospitalizations.
Medicare officials tentatively plan to restrict the use of a controversial Alzheimer’s drug to only those patients participating in clinical trials, while the Department of Health and Human Services looks into lowering the monthly Medicare Part B premium. Meanwhile, covid confusion still reigns, as the Biden administration moves, belatedly, to make more masks and tests available. Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.
On Jan. 1, California started buying prescription drugs for its nearly 14 million Medicaid enrollees, a responsibility that had primarily been held by managed-care insurance plans. State officials estimate California will save hundreds of millions of dollars by flexing its purchasing power, but some health clinics expect to lose money.
Predominantly Black and Hispanic urban areas are more likely than white neighborhoods to see local pharmacies close and are more likely to be pharmacy deserts. In Chicago, one pharmacist is bucking the trend, operating the drugstore his father opened in the 1960s in a Black neighborhood.
Sen. Joe Manchin (D-W.Va.) dealt a blow to congressional efforts to pass President Joe Biden’s domestic agenda bill, forcing Democrats to regroup starting in 2022. Meanwhile, the omicron covid variant spreads rapidly in the U.S., threatening the stability of the nation’s health care system. Joanne Kenen of Politico and the Johns Hopkins School of Public Health, Rachel Cohrs of Stat and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more, plus a look back at the year in health policy. Also this week, Rovner interviews Ceci Connolly, president and CEO of the Alliance of Community Health Plans.
Stores like Walmart and Shopko opened pharmacies in small towns, either buying out the local pharmacy or driving it out of business. What happens when those chains later withdraw, leaving communities with no pharmacy?
Independent pharmacists who want to retire often have trouble attracting new pharmacists to take over their practices, particularly in rural areas. That can cause smaller towns to lose their pharmacies. With many pharmacists near retirement, the problem may only get worse.
© 2026 KFF